Literature DB >> 12021195

Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220.

Oleg G Chepurny1, Mehboob A Hussain, George G Holz.   

Abstract

Signal transduction properties of exendin-4 (Ex-4) underlying its ability to stimulate rat insulin I gene promoter (RIP1) activity were assessed in the pancreatic beta-cell line INS-1. Ex-4 acted via glucagon-like peptide-1 receptors to stimulate RIP1 in a glucose-dependent manner, as measured in cells transfected with a -410-bp RIP1-luciferase construct (RIP1-Luc). The action of Ex-4 was independent of cAMP and PKA because it was not blocked by cotransfection with dominant-negative G alpha(s), was unaffected by pretreatment with the membrane-permeant cAMP antagonist 8-Br-Rp-cAMPS, and remained apparent after treatment with PKA inhibitors H-89 or KT 5720. Similarly, cotransfection with a dominant-negative isoform of the type-2 cAMP-regulated guanine nucleotide exchange factor (Epac2) failed to alter the response to Ex-4. Ro 31-8220, a serine/threonine protein kinase inhibitor that targets PKC as as well as the 90-kDa ribosomal S6 kinase (RSK) and mitogen- and stress-activated protein kinase (MSK) family of cAMP response element-binding protein (CREB) kinases, blocked the stimulatory action of Ex-4 at RIP1-Luc. However, selective inhibition of PKC using K-252c, prolonged exposure to phorbol 1,2-myristate-13-acetate, or cotransfection with dominant-negative atypical PKC-zeta, was without effect. A-CREB, a dominant-negative inhibitor of basic region-leucine zipper transcription factors (bZIPs) related in structure to CREB, inhibited the action of Ex-4 at RIP1-Luc, whereas A-ATF-2 was ineffective. Similarly, introduction of deletions at the RIP1 cAMP response element (CRE), or truncation of RIP1 to remove the CRE, nearly abolished the action of Ex-4. Inactivating mutations introduced at the A4/A3 elements, binding sites for the glucose-regulated homeodomain transcription factor PDX-1, did not diminish the response to Ex-4, although a marked reduction of basal promoter activity was observed. The glucose-dependent stimulation of RIP1-Luc by Ex-4 was reproduced using a synthetic reporter (RIP1-CRE-Luc) incorporating multimerized CREs of the RIP1 nonpalindromic sequence 5'-TGACGTCC-3'. It is concluded that the bZIP and CRE-mediated stimulation of RIP1 by Ex-4 explains, at least in part, how this insulinotropic hormone facilitates transcriptional activity of the rat insulin I gene.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021195      PMCID: PMC3500996          DOI: 10.1210/endo.143.6.8870

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  59 in total

1.  Expression of cAMP-regulated guanine nucleotide exchange factors in pancreatic beta-cells.

Authors:  C A Leech; G G Holz; O Chepurny; J F Habener
Journal:  Biochem Biophys Res Commun       Date:  2000-11-11       Impact factor: 3.575

2.  Involvement of calmodulin in glucagon-like peptide 1(7-36) amide-induced inhibition of the ATP-sensitive K+ channel in mouse pancreatic beta-cells.

Authors:  W G Ding; H Kitasato; H Matsuura
Journal:  Exp Physiol       Date:  2001-05       Impact factor: 2.969

3.  Specificity and mechanism of action of some commonly used protein kinase inhibitors.

Authors:  S P Davies; H Reddy; M Caivano; P Cohen
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

4.  Activating transcription factor-2 is a positive regulator in CaM kinase IV-induced human insulin gene expression.

Authors:  N Ban; Y Yamada; Y Someya; Y Ihara; T Adachi; A Kubota; R Watanabe; A Kuroe; A Inada; K Miyawaki; Y Sunaga; Z P Shen; T Iwakura; K Tsukiyama; S Toyokuni; K Tsuda; Y Seino
Journal:  Diabetes       Date:  2000-07       Impact factor: 9.461

5.  Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element.

Authors:  G Skoglund; M A Hussain; G G Holz
Journal:  Diabetes       Date:  2000-07       Impact factor: 9.461

6.  Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism.

Authors:  X Wang; J Zhou; M E Doyle; J M Egan
Journal:  Endocrinology       Date:  2001-05       Impact factor: 4.736

7.  cAMP-GEFII is a direct target of cAMP in regulated exocytosis.

Authors:  N Ozaki; T Shibasaki; Y Kashima; T Miki; K Takahashi; H Ueno; Y Sunaga; H Yano; Y Matsuura; T Iwanaga; Y Takai; S Seino
Journal:  Nat Cell Biol       Date:  2000-11       Impact factor: 28.824

8.  Glucagon-like peptide 1 stimulates lipolysis in clonal pancreatic beta-cells (HIT).

Authors:  G C Yaney; V N Civelek; A M Richard; J S Dillon; J T Deeney; J A Hamilton; H M Korchak; K Tornheim; B E Corkey; A E Boyd
Journal:  Diabetes       Date:  2001-01       Impact factor: 9.461

9.  Insulinotropic hormone glucagon-like peptide 1 (GLP-1) activation of insulin gene promoter inhibited by p38 mitogen-activated protein kinase.

Authors:  D M Kemp; J F Habener
Journal:  Endocrinology       Date:  2001-03       Impact factor: 4.736

10.  Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.

Authors:  R Ritzel; M Schulte; N Pørksen; M S Nauck; J J Holst; C Juhl; W März; O Schmitz; W H Schmiegel; M A Nauck
Journal:  Diabetes       Date:  2001-04       Impact factor: 9.461

View more
  21 in total

1.  Epac-selective cAMP analog 8-pCPT-2'-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic beta-cells.

Authors:  Guoxin Kang; Jamie W Joseph; Oleg G Chepurny; Marie Monaco; Michael B Wheeler; Johannes L Bos; Frank Schwede; Hans-G Genieser; George G Holz
Journal:  J Biol Chem       Date:  2002-12-20       Impact factor: 5.157

2.  Glucose-dependent potentiation of mouse islet insulin secretion by Epac activator 8-pCPT-2'-O-Me-cAMP-AM.

Authors:  Grant G Kelley; Oleg G Chepurny; Frank Schwede; Hans-G Genieser; Colin A Leech; Michael W Roe; Xiangquan Li; Igor Dzhura; Elvira Dzhura; Parisa Afshari; George G Holz
Journal:  Islets       Date:  2009 Nov-Dec       Impact factor: 2.694

3.  Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP.

Authors:  Oleg G Chepurny; Minos-Timotheos Matsoukas; George Liapakis; Colin A Leech; Brandon T Milliken; Robert P Doyle; George G Holz
Journal:  J Biol Chem       Date:  2019-01-08       Impact factor: 5.157

Review 4.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

Review 5.  Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.

Authors:  K Pabreja; M A Mohd; C Koole; D Wootten; S G B Furness
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 6.  Mechanisms of action of glucagon-like peptide 1 in the pancreas.

Authors:  Máire E Doyle; Josephine M Egan
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein.

Authors:  Sita Aggarwal; Seung-Wook Kim; Seung-Hee Ryu; Wen-Cheng Chung; Ja Seok Koo
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

Review 9.  Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation.

Authors:  Han Xie; Natesh Yepuri; Qinghe Meng; Ravi Dhawan; Colin A Leech; Oleg G Chepurny; George G Holz; Robert N Cooney
Journal:  Rev Endocr Metab Disord       Date:  2020-08-26       Impact factor: 6.514

10.  Mechanisms for suppression of interleukin-6 expression in peritoneal macrophages from docosahexaenoic acid-fed mice.

Authors:  Yuhui Shi; James J Pestka
Journal:  J Nutr Biochem       Date:  2008-07-07       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.